Clinical trial
CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
NCT05436093 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- June 23, 2022
- Completion date
- December 31, 2027
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumor